1.Leucocytic DNA Methylation of Interleukin-6 Promoter Reduction in Pre-Hypertensive Young Adults
Wan Fatein Nabeila Wan Omar ; Aszrin Abdullah ; Norlelawati A Talib ; Azarisman Shah Mohd Shah ; Jamalludin AJamalludin Ab RahmanAb Rahman
Malaysian Journal of Medical Sciences 2019;26(6):46-54
Background: Pre-hypertension is associated with increased risk of cardiovascular disease.
Chronic inflammation plays an important role in the pathophysiology of essential hypertension,
with epigenetic dysregulation involvement. Nevertheless, the role of DNA methylation in prehypertensive
state is unknown. The aim of this study was to investigate the association between
DNA methylation level of interleukin-6 (IL-6) promoter in pre-hypertensive (PreHT) and
normotensive (NT) young adults.
Methods: A total of 80 NT and 80 PreHT healthy subjects aged between 18–45 years were
recruited in Kuantan, Pahang, Malaysia using an observational cross-sectional study approach.
DNA methylation level of IL-6 promoter in peripheral leukocytes were measured using bisulphite
conversion and MethyLight assay.
Results: There was no significant difference in age between NT and PreHT (P = 0.655).
The mean blood pressure was 110(8)/73(5) mmHg in NT and 125(7)/82(5) mmHg in PreHT
subjects. The IL-6 promoter methylation level was significantly lower in PreHT compared to NT
subjects (P < 0.001).
Conclusion: The current study demonstrates that hypomethylation of IL-6 promoter
was associated with pre-hypertension in young adults. Thus, IL-6 methylation could be used as
an early indicator for predicting hypertension and related risk of cardiovascular diseases in prehypertensive
subjects. Gene expression and longitudinal studies are warranted to examine the
methylation effect on IL-6 expression over time